Aktuellt
SENASTE
Yesterday the FDA announced safety concerns towards JAK inhibitors following a review of a large randomized safety clinical trial. In our view, this strengthens Cobitolimods position as a safe and effective treatment for moderate to severe UC. We maintain our view that the current valuation of InDex does not justify the value of cobitolimod. We reiterate our Base case of SEK 4.5.
LÄS MER
